Clinical trial • Phase IV • Other
Levonorgestrel for Post-medical abortion contraception
Phase IV trial of Levonorgestrel for Post-medical abortion contraception.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Post-medical abortion contraception
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 28-09-2024
- First CTIS Authorization Date
- 09-10-2024
Trial design
Randomised, open-label, immediate insertion of intrauterine contraception versus delayed insertion at 2-4 weeks post abortion-controlled Phase IV trial across 7 sites in Sweden.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Immediate insertion of intrauterine contraception versus delayed insertion at 2-4 weeks post abortion
- Target Sample Size
- 720
- Trial Duration For Participant
- 365
Eligibility
Recruits 720 Vulnerable population selected. Exclusion criterion: "inability to give informed consent." Subject information and informed consent form documents are listed in the trial documents..
- Vulnerable Population
- Vulnerable population selected. Exclusion criterion: "inability to give informed consent." Subject information and informed consent form documents are listed in the trial documents.
Inclusion criteria
- {"criterion_text":"- above 18 years old\n- eligible for medical abortion\n- opting for post abortion Intrauterine contraception\n- able and willing to comply with planned follow up"}
Exclusion criteria
- {"criterion_text":"- contraindication for medical abortion\n- contraindication for intrauterine contraception (contraindications may be present for LNG- IUSs but the woman may still choose a Cu-IUD and thereby enter the study),\n- inability to give informed consent.\n- Septic abortion"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The proportion of women in each group (immediate or delayed) using intrauterine contraception as contraception at 6 months post abortion","definition_or_measurement_approach":"Proportion of women in each group using intrauterine contraception at 6 months post abortion (measured as use of IUC at 6 months post abortion)."}
Secondary endpoints
- {"endpoint_text":"- Use of IUC at 3, 6 and 12 months post insertion evaluated by telephone or e-mail follow-up (continued use/voluntary discontinued use, involuntary discontinued use including expulsions etc) reasons for discontinuation will be recorded and subsequent use of other contraceptive methods will be noted)","definition_or_measurement_approach":"Measured by telephone or e-mail follow-up at 3, 6 and 12 months; continued use, voluntary/involuntary discontinuation, reasons and subsequent contraceptive use recorded."}
- {"endpoint_text":"- Difference in the proportion of women who successfully have the IUC inserted (success versus failure),","definition_or_measurement_approach":"Proportion of successful versus failed insertions recorded."}
- {"endpoint_text":"- Ease of insertion according to health care provider (judged as very easy, easy, moderately, or very difficult)","definition_or_measurement_approach":"Provider-judged ease of insertion categorized as very easy, easy, moderately, or very difficult."}
- {"endpoint_text":"- pain at time of insertion (women will indicate the pain before insertion, at placement of tenaculum, sound and IUC by putting a vertical mark on a 10 cm long horizontal line with a Visual Analogue Scale (VAS) from 0, indicating no pain to 10 indicating worst imaginable pain. Result will be noted in millimeters and entered into case report forms).","definition_or_measurement_approach":"Pain measured using a 10 cm Visual Analogue Scale (VAS); marks converted to millimetres and entered into case report forms."}
- {"endpoint_text":"- Post-abortion bleeding (number of days of fresh bleeding and spotting after the abortion)","definition_or_measurement_approach":"Number of days of fresh bleeding and spotting recorded post-abortion."}
- {"endpoint_text":"- Reasons for non-attempted insertion of IUC (change of mind, heavy bleeding, not coming for insertion, staff being unavailable etc),","definition_or_measurement_approach":"Reasons for non-attempted insertion documented (e.g., change of mind, heavy bleeding, no show, staff unavailable)."}
- {"endpoint_text":"- Pregnancies occurring during the 6 and 12 month follow-up (planned and unplanned, wanted and unwanted, pregnancy outcomes- ectopic, miscarriage, abortion, molar, kept pregnancy),","definition_or_measurement_approach":"Pregnancies during 6 and 12 month follow-up recorded with outcomes (ectopic, miscarriage, abortion, molar, continued pregnancy)."}
- {"endpoint_text":"- Acceptability of immediate and delayed insertion of IUC by asking women if they would recommend the procedure to a friend (yes/no, asked at the time of insertion and at the 3 and 6 month follow up),","definition_or_measurement_approach":"Acceptability assessed by asking participants yes/no if they would recommend the procedure at insertion and at 3- and 6-month follow-ups."}
- {"endpoint_text":"- Acceptability of IUC as post abortion contraception- evaluated as above,","definition_or_measurement_approach":"Acceptability of IUC as post-abortion contraception evaluated similarly (participant responses recorded)."}
- {"endpoint_text":"- Expulsion rate during 12 months following insertion in both groups evaluated by telephone follow up at 3, 6 and 12 months post abortion (complete, partial or no expulsion. The exact day of expulsion will be noted to determine the risk of expulsion as a function of time post insertion),","definition_or_measurement_approach":"Expulsion rate assessed by telephone follow-up at 3, 6 and 12 months; complete/partial/no expulsion recorded and exact day of expulsion noted."}
- {"endpoint_text":"- Complications (adverse events (AE) and serious AE) bleeding requiring any treatment, uterine perforations and cervical tears, infection requiring treatment with antibiotics, hospitalization for any reason, surgical procedures due to heavy bleeding, incomplete abortions, prolonged bleeding or patient request,","definition_or_measurement_approach":"Complications and adverse events (including bleeding requiring treatment, perforations, tears, infections requiring antibiotics, hospitalizations, surgical procedures) recorded."}
- {"endpoint_text":"- The proportion of surgical procedures in total and for each study site (type of procedure, reasons therefore- infection, retained products of conception, prolonged bleeding etc).","definition_or_measurement_approach":"Proportion and type of surgical procedures recorded overall and by site, with reasons (infection, retained products, prolonged bleeding, etc.)."}
Recruitment
- Planned Sample Size
- 720
- Recruitment Window Months
- 65
- Consent Approach
- Informed consent to be obtained from participants; inclusion restricted to adults ("above 18 years old"). Exclusion includes "inability to give informed consent." Subject information and informed consent form documents are listed in the trial documents. No assent process or languages are specified in the available data.
Geography
- Total Number Of Sites
- 7
- Total Number Of Participants
- 720
Sweden
- Earliest CTIS Part Ii Submission Date
- 28-09-2024
- Latest Decision Or Authorization Date
- 09-10-2024
- Processing Time Days
- 11
- Number Of Sites
- 7
- Number Of Participants
- 720
Sites
- Site Name
- Uppsala University Hospital
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Emma Håstad
- Principal Investigator Email
- emma.hastad@akademiska.se
- Contact Person Name
- Emma Håstad
- Contact Person Email
- emma.hastad@akademiska.se
- Site Name
- Danderyds Sjukhus AB
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Helena Kopp Kallner
- Principal Investigator Email
- helena.kopp-kallner@ki.se
- Contact Person Name
- Helena Kopp Kallner
- Contact Person Email
- helena.kopp-kallner@ki.se
- Site Name
- Region Dalarna
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Sara Hogmark
- Principal Investigator Email
- sara.hogmark@regiondalarna.se
- Contact Person Name
- Sara Hogmark
- Contact Person Email
- sara.hogmark@regiondalarna.se
- Site Name
- Sahlgrenska University Hospital-Vaestra Goetalandsregionen
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Helena Hognert
- Principal Investigator Email
- helena.hognert@vgregion.se
- Contact Person Name
- Helena Hognert
- Contact Person Email
- helena.hognert@vgregion.se
- Site Name
- Karolinska University Hospital
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Kristina Gemzell
- Principal Investigator Email
- kristina.gemzell@ki.se
- Contact Person Name
- Kristina Gemzell
- Contact Person Email
- kristina.gemzell@ki.se
- Site Name
- Soedersjukhuset AB
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Cecilia Berger
- Principal Investigator Email
- cecilia.berger@regionstockholm.se
- Contact Person Name
- Cecilia Berger
- Contact Person Email
- cecilia.berger@regionstockholm.se
- Site Name
- Lund University Hospital
- Department Name
- dept of Ob/gyn
- Principal Investigator Name
- Pia Teleman
- Principal Investigator Email
- pia.teleman@skane.se
- Contact Person Name
- Pia Teleman
- Contact Person Email
- pia.teleman@skane.se
Sponsor
Primary sponsor
- Full Name
- Karolinska Institutet
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- Mirena 20 mikrogram/24 timmar intrauterint inlägg
- Active Substance
- Levonorgestrel
- Modality
- Small molecule
- Routes Of Administration
- INTRAUTERINE USE
- Route
- INTRAUTERINE USE
- Authorisation Status
- Authorised
- Starting Dose
- Mirena 20 mikrogram/24 timmar intrauterint inlägg
- Frequency
- Single insertion; duration up to 96 months
- Investigational Product Name
- Kyleena® 19,5 mg, intrauterint inlägg
- Active Substance
- Levonorgestrel
- Modality
- Small molecule
- Routes Of Administration
- INTRAUTERINE USE
- Route
- INTRAUTERINE USE
- Authorisation Status
- Authorised
- Starting Dose
- Kyleena® 19,5 mg, intrauterint inlägg
- Frequency
- Single insertion; duration up to 60 months
- Investigational Product Name
- Jaydess 13,5 mg, intrauterint inlägg
- Active Substance
- Levonorgestrel
- Modality
- Small molecule
- Routes Of Administration
- INTRAUTERINE USE
- Route
- INTRAUTERINE USE
- Authorisation Status
- Authorised
- Starting Dose
- Jaydess 13,5 mg, intrauterint inlägg
- Frequency
- Single insertion; duration up to 36 months
Related trials
Other published trials that may interest you.